Biopharmaceutical Company
Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities. HR 4302 Protecting Access to Medicare Act of 2014 - Public Law No: 113-93 
In the above the specific issues included potential Medicare offsets that might be applied to prescription drugs H.R.4187 -- Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 FY 2014 Omnibus HR 3547 
FY 2014 Continuing Resolution H J Res 106 PL 113-73 
FY 2014 Continuing Resolution H J Res 59 PL 113-67 
FY 2015 Budget, H Con Res 96 (no Senate Companion at this time)
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs Implementation of the "GAIN" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation 
HR 3742 -- the Antibiotic Development to Advance Patient Treatment Act of 2013 
H.R.4187 -- Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 
antibiotic product incentives for possible inclusion in the House "21st Century Cures" effort
HCR - Health Issues MMM - Medicare/Medicaid BUD - Budget/Appropriations PHA - Pharmacy
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
SLC HEALTH STRATEGIES, LLC
9710 Traville Gateway Drive, Number 157, Rockville, MD, 20850, US
SHARON COHEN SHARON COHEN SHARON COHEN SHARON COHEN